Advanced Micro Devices (AMD) seeks to beef up competing AI games NVIDIA (NVDA) leads this weekend’s watchlist of five stocks approaching the buy point. dyna trace(DT) software platform monitors IT networks and predicts and solves problems with AI and automation. Participating in AMD stocks and DT is Marriott International (March), Las Vegas Sands (LVS) and new S&P 500 members Inlet (PODD) manufactures tubeless insulin pumps that you wear on your body.
X
LVS, which has casino properties in Macau and Singapore recovering after the lifting of Covid restrictions, is part of the IBD Leaderboard portfolio of elite stocks. DT stock is part of the flagship IBD 50 list of leading growth stocks and is a new addition to SwingTrader’s portfolio.
Friday’s stock market action saw the S&P 500 rise sharply from its 50-day moving average. It kept the rally intact after the Federal Reserve hinted at a moratorium on rate hikes on Wednesday. But the economic backdrop remains worrying, with bank troubles and debt ceilings likely to increase volatility. So read IBD’s The Big Picture every day to stay informed on where the market is heading and what it means for your trading decisions.
AMD Stocks
AMD’s stock fell 9% on Wednesday after a volatile week, posting smaller-than-expected declines in quarterly earnings and earnings, but announced a below-consensus revenue outlook for the second quarter. . Still, AMD has shown a second-half acceleration led by chips for the data center and is launching new offerings.
AMD shares surged 6% on Thursday after Bloomberg reported a major collaboration with Microsoft on an AI chip. The partnership seemed less important after Microsoft disputed the Bloomberg article, but AMD’s shares rose 3.7% to 89.84 on Friday, regaining the 50-day line. .
A decisive move beyond 50 days could create an early entry opportunity. Turn it into a potential buy, hoping that AMD’s stock hits 91.74, 10 cents above Thursday’s high. AMD shares have an official buy point of 102.53 from his six-week consolidation, according to MarketSmith analysis.
DT Stock
DT stock was featured as Thursday’s IBD Stock Of The Day. This article highlights analysts’ views that the Grail platform’s artificial intelligence and automation capabilities give Dynatrace an edge over competitors such as: data dog (DDOG) and Cisco Systems (CSCO).
These capabilities are in high demand right now as companies look to optimize their cloud spending in a challenging operating environment for technology companies. This optimization is hurting the performance of big cloud companies such as Amazon’s AWS.
DT’s shares rose 0.7% to 43.96 on Friday after surging in Datadog’s earnings on Thursday. DT stock is now viable after last week’s rally below his 50-day line, breaking the trendline from its recent peak on Feb. 7, and clearing its April 19 high of 43.42 .
The official buy point from the 13-week cup base is 48.10, but this entry high may not be optimal given the uncertain market backdrop.
Dynatrace was added to the S&P MidCap 400 Index last September.
March stock
Marriott International posted comfortable earnings Tuesday, with EPS up 67% to $2.09 and revenues up 34% to $5.615 billion. Marriott has raised its EPS outlook for 2023 to a range of $7.97-8.42 from $7.23-7.91. Analysts had expected $7.74.
Bernstein analyst Richard Clark raised his price target on MAR stock to 204 from 178, outperforming the rating.He emphasized Marriott’s lead in accelerating earnings per available room and potential net unit growth, while discounting MAR shares Hilton (HLT) is illegal.
The March stock rose 5% on Tuesday’s earnings call and then hit resistance as it tested the 181.65 buy point from the 54-week base of the cup with handles. A 12-week handle is long enough to be considered a base.
Investors may have seen Tuesday’s clearing of 175.21 as an early entry in the 12-week consolidation or buying point for the handle.
On the weekly chart, the line of relative strength for MAR stocks, the blue line that shows progress against the S&P 500 on the IBD chart, hit new highs in the past week.
Marriott and other travel stocks have had a tricky move over the past year, showing bullish moves before falling.
LVS Stock
Las Vegas Sands stock entered a buying range on April 20 following its first quarter earnings report. More positive news on travel and gaming trends following the end of China’s Covid lockdown continues to boost LVS shares.
Earlier last week, LVS shares surged for the first time in two years after Macau officials reported April gaming revenue jumped to MOP14.72 billion ($1.82 billion), up 450% from a year earlier. High price reached.
Las Vegas Sands has five properties in Macau and one in Singapore.
LVS shares fell 0.1% to 61.65 on Friday, down 3.45% for the week. LVS inventory has a buy point of 60.40 from the base of the cup with handles. The buy zone continues until 63.42.
PODDStock
Insulet beat first-quarter earnings expectations after Thursday’s close, posting adjusted EPS of 34 cents, down from 11 cents forecast, down from 40 cents a year ago. Revenue increased 21% to $358.1 million versus an estimated $330.9 million. Results include a 98% drop in non-core drug delivery revenues, so the trend is stronger than it looks.
Insulet has raised its 2023 growth forecast to 18%-22% from 14%-19%. Omnipod insulin pump sales in the US are up 27% to 31% from the previous guidance of 21% to 26%.
Baird analyst Jeff Johnson has raised his price target on PODD stock to 3,750 from 350.
PODD shares rose 2% to 328.76 on Friday. PODD stock is in a buy range above the 320.10 buy point, 10 cents higher than the Nov. 4 high. Prior to the profit move, PODD stock carved out a tight five-week pattern, with gains or losses of 1.5% or less. It offers 328.97 entries.
Insulet replaced SVB Financial Group in the S&P 500 in March.
You may also like:
These are the 5 best stocks to buy and watch right now
Join IBD Live and learn from the pros how to read top charts and trading techniques
Find the best growth stocks to buy and watch
IBD Digital: Unlock IBD’s premium stock listings, tools and analytics
Stock prices skyrocket, but don’t run wild just yet. What should investors do now?
